Pharmabcine Inc. has received approval from the human research ethics committee (HREC) in Australia for a phase Ia/b trial of PMC-309, a monoclonal antibody against the human V-domain Ig suppressor of T-cell activation (VISTA) ligand.
Researchers from China Pharmaceutical University and Nanjing First Hospital synthesized and optimized a novel series of thiohydantoin based compounds leading to the discovery of candidate [I] as the lead androgen receptor (AR) antagonist (IC50=1.46 µM).
Five years after Gilead Sciences Inc. gave up on momelotinib in the wake of two phase III failures in myelofibrosis, the JAK1/2 and ACVR1 inhibitor has found its way to the market in the hands of GSK plc. Branded Ojjaara, the drug gained U.S. FDA approval for use in intermediate- or high-risk myelofibrosis patients with anemia regardless of prior administration with JAK inhibitors such as Jakafi (ruxolitinib, Incyte Corp.).
Cancer Research Technology Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently bonded to a mitogen-activated protein kinase 7 (MAPK7; ERK5)-targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Researchers from Xiamen University and affiliated organizations have reported the discovery of nuclear hormone receptor NUR/77 (Nur77) modulators as potential candidates for the treatment of hepatocellular carcinoma (HCC).
Researchers from Peking University Cancer Hospital presented the discovery and preclinical evaluation of [124I]IMMU-132, a trophoblast cell surface antigen 2 (Trop2)-targeting molecular probe for micro-PET imaging.
Integrin alphavbeta3 and aminopeptidase N (CD13) are important biomarkers involved in tumor angiogenesis, tumor growth and metastasis. Peptides RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) are the most studied peptides for targeting integrin alphavbeta3 and CD13, respectively.
Medigene AG has selected its lead candidate for MDG-2011, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12V with HLA-A*11 and being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.
Retinoic acid (RA) is fundamental to maintain immune homeostasis. In this process, RA induces regulatory T cells and promotes tolerance, but depending on the conditions, RA may also promote inflammation and tissue damage.
RSS
